Plasma concentrations of myeloid-derived growth factor in healthy individuals and patients with acute myocardial infarction as assessed by multiple reaction monitoring-mass spectrometry

• Verfasst von: Polten, Felix [VerfasserIn]
• Verfasst von: Giannitsis, Evangelos [VerfasserIn]
• Titel: Plasma concentrations of myeloid-derived growth factor in healthy individuals and patients with acute myocardial infarction as assessed by multiple reaction monitoring-mass spectrometry
• Verf.angabe: Felix Polten, Marc R. Reboll, Christian Widera, Tibor Kempf, Kerstin Bethmann, Priyanka Gupta, John Miglietta, Anton Pekcec, Jochen Tillmanns, Johann Bauersachs, Evangelos Giannitsis, Andreas Pich, and Kai C. Wollert
• Jahr: 2019
• Jahr des Originals: 2018
• Umfang: 7 S.
• Fussnoten: Published: December 13, 2018 ; Gesehen am 15.03.2019
• Titel Quelle: Enthalten in: Analytical chemistry
• Ort Quelle: Columbus, Ohio : American Chemical Society, 1947
• Jahr Quelle: 2019
• Band/Heft Quelle: 91(2019), 2, Seite 1302-1308
• ISSN Quelle: 1520-6882
• DOI: doi:10.1021/acs.analchem.8b03041
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1590344421

Abstract

Myeloid-derived growth factor (MYDGF in humans, Mydgf in mice) is a secreted protein with previously unknown biological functions. In a recent study, Mydgf was shown to mediate cardiac repair after acute myocardial infarction (MI) in mice. Lack of a sensitive assay to measure MYDGF in the circulation has hampered its further investigation. Here, we developed a liquid chromatography/multiple reaction monitoring-mass spectrometry MYDGF assay, employing SDS-PAGE-based protein fractionation to deplete high-abundant proteins and a stable isotope-labeled synthetic standard peptide for quantification. The assay had a lower limit of quantification of 0.8 ng/mL and a linear range up to 190 ng/mL. Within-run and total imprecision ranged from 8 to 17% and 11 to 20%, respectively. MYDGF plasma concentrations were not affected by either storage at room temperature for 4 h or up to three freeze-thaw cycles. Apparently healthy adults presented with a median (range) MYDGF concentration of 3.3 (1.3-6.7) ng/mL (n = 120). MYDGF concentrations were elevated 2.7-fold (P < 0.001) in patients with acute MI (n = 101) and were associated with inflammatory biomarkers, renal dysfunction, and long-term cardiovascular mortality. The new assay and the favorable preanalytic characteristics of the analyte will facilitate studies into the pathophysiology of MYDGF and its potential use as a biomarker or protein therapeutic in patients with acute MI or other disease states.